Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

Joel Rivera-Concepcion; Dipesh Uprety; Alex A. Adjei

doi:10.4143/crt.2022.078

Cancer Research and Treatment > Volume 54(2); 2022 > Article

Rivera-Concepcion, Uprety, and Adjei: Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

Review Article

Cancer Res Treat. 2022; 54(2): 315-329.

Published online: February 18, 2022

DOI: https://doi.org/10.4143/crt.2022.078

Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

Joel Rivera-Concepcion¹

, Dipesh Uprety², Alex A. Adjei¹

¹Department of Oncology, Mayo Clinic, Rochester, MN, USA

²Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

Correspondence: Alex A. Adjei, Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA,
Tel: 1-507-284-2511, Fax: 1-507-284-1803, E-mail: adjei.alex@mayo.edu

Received February 12, 2022 Accepted February 16, 2022

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Precision oncology has fundamentally changed how we diagnose and treat cancer. In recent years, there has been a significant change in the management of patients with oncogene-addicted advanced-stage non–small cell lung cancer (NSCLC). Increasing amounts of identifiable oncogene drivers have led to the development of molecularly targeted drugs. Undoubtedly, the future of thoracic oncology is shifting toward increased molecular testing and the use of targeted therapies. For the most part, these novel drugs have proven to be safe and effective. As with all great innovations, targeted therapies pose unique challenges. Drug toxicities, resistance, access, and costs are some of the expected obstacles that will need to be addressed. This review highlights some of the major challenges in the use of targeted therapies in NSCLC and provides guidance for the future strategies.

Key words: Lung neoplasms, Non-small cell lung carcinoma, Targeted therapy, Challenges, Cost, Drug resistance, Toxicity

Introduction

Lung cancer is the second most common cancer world-wide and the leading cause of cancer-related deaths [1]. Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all new lung cancer cases and more than two-thirds of these cases are metastatic at the time of diagnosis [2]. For decades, cytotoxic chemotherapy in the form of a platinum-doublet was the standard of care for advanced stage disease. While these therapies are associated with increased survival and improved quality of life, the responses achieved by chemotherapeutic agents are modest and there is a lack of durable clinical benefit [3–5].

Advances in genomics leading to identification of oncogenic driver gene aberrations have revolutionized the practice of thoracic oncology. Significant improvements in response rates and greater than 3-year median survival in the metastatic setting is now seen in subsets of patients. Although molecular targeted therapies were initially used in the late 1990s in patients with NSCLC in the form of gefitinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), initial response rates were approximately 10% for the unselected NSCLC population. IPASS (Iressa Pan-Asia Study) was the first phase III study which demonstrated an improved outcome with oral gefitinib when compared with carboplatin-paclitaxel in patients with EGFR-mutant NSCLC [6]. In this trial, the objective response rate with oral gefitinib was 71% versus 1% between the EGFR-mutant and wild-type patients respectively [6]. Since then, multiple other TKIs targeting specific molecular pathways have been developed. Targeted therapies inhibit protein products of aberrant genes that drive tumors to continuously proliferate and survive. Drugs have been developed with a wide range of mechanisms of action. One of the most common drug mechanisms is the inhibition of tyrosine phosphorylation of target proteins by small molecule TKIs that compete with ATP-binding to the tyrosine kinase domain of proteins and thereby block protein phosphorylation and inhibit the proliferation and oncogenic signals through a number of signaling pathways such as the RAS-MAPK (mitogen-activated protein kinase), PI3K (phosphoinositide 3-kinase)-AKT-mTOR (mammalian target of rapamycin), and JAK/STAT pathways [7]. Drugs like osimertinib, alectinib, larotrectinib, crizotinib, among others are in this class. In contrast, the MEK inhibitor trametinib is an ATP non-competitive inhibitor that binds MEK adjacent to the ATP-binding site in common with other MEK allosteric inhibitors [8]. A different mechanism is also exhibited by the KRAS G12C inhibitors such as sotorasib, which binds covalently to the KRAS mutated cysteine 12 residue at the switch II pocket [9]. Emerging evidence has demonstrated that antibody-drug conjugates (ADCs) are active in NSCLC. In essence, ADCs are composed of a monoclonal antibody linked to a cytotoxic payload via a linker. They are designed to deliver these drugs to cells that express the target antigen of the selected antibody [10]. As an example, trastuzumab deruxtecan is an ADC which consists of a humanized immunoglobulin G1 antibody against human epidermal growth factor receptor 2 (HER2) conjugated to a topoisomerase I inhibitor payload by a cleavable tetrapeptide-based linker. Recent clinical data demonstrate encouraging results in NSCLC [11,12]. Currently, oncogenic aberrations in eight genes (EGFR, ALK, ROS1, BRAF, KRAS, NTRK, MET, and RET) have U.S. Food and Drug Administration (FDA) approved therapies. These agents have typically been used in the metastatic setting (Table 1) [13–35]. However, the use of these agents in earlier stages of disease have gained recent interest. A phase III study of osimertinib in early-stage resectable EGFR-mutant NSCLC has shown improvement in disease-free survival, and now is FDA approved [36]. Various clinical trials designed to incorporate other targeted therapies in the adjuvant setting are underway [37]. As we attempt to enhance the excellent clinical activity of these agents and develop curative strategies, complexities and challenges emerge. This review discusses some of the challenges in the use of targeted therapies in NSCLC and provides guidance for future strategies. The major challenges hampering the expanded use of targeted agents to potentially achieve cure of advanced NSCLC are resistance in its different forms, toxicity, and high cost of these agents limiting access by all NSCLC patients.

Drug Resistance

There are varied responses of NSCLC patients’ tumors to targeted therapies. A few patients will achieve a complete response, others a partial response and yet in some others, there is no objective response to therapy. Even with our most effective agents, the best initial response rates are around 70%–80% [18,38]. The tumors that fail to respond are deemed to have primary resistance. Unfortunately, even in those who do respond, disease progression inevitably occurs due to acquired resistance. These resistance mechanisms, primary and acquired resistance, are discussed below.

1. Primary resistance

Primary resistance or intrinsic resistance can be defined as the lack of initial treatment response despite the presence of a targetable driver mutation. Although there is a paucity of data, various factors are known to play a role in primary resistance. Differential sensitivities to TKI therapy based on mutation-subtype, pharmacology of the drug and adherence to treatment play a significant role [39–42]. Tumor cells within the same tumor site or between different metastatic tumor sites within the same host do not necessarily share uniform characteristics, including histology, metastatic or proliferative potential and molecular signatures. This is referred to as tumor heterogeneity [43]. At the histologic level, one can have adeno-squamous cancers or pleomorphic cancer with adenocarcinoma or adenocarcinoma features. Additionally, many studies have shown significant genetic diversity in the same patients from different metastatic sites [41,42]. Jamal-Hanjani et al. [41], in their prospective study, performed multi-region whole-exome sequencing in 100 patients at 327 tumor regions with early-stage NSCLC after surgical resection but before the receipt of adjuvant chemotherapy. The study demonstrated extensive intratumor heterogeneity suggesting genomic instability processes during tumor development. Although originating from the same clone, it has been hypothesized that the tumor cells adapt to various environmental insults via a Darwinian-like selection mechanism and a subpopulation of cells undergo genotypic and/or phenotypic changes to transform themselves to drug-resistant clones [44]. Tumor heterogeneity therefore plays a crucial role in disease progression especially in patients with an oncogenic-addicted lung cancer where a TKI is utilized to target a specific driver mutation [45].

2. Acquired resistance

There is presumed acquired resistance when there is tumor progression after an initial objective response. In 2010, Jackman et al. [46] provided a guideline to define acquired resistance to EGFR TKIs in NSCLC. These general concepts, with some adaptations, can be used as a general guide for the clinical definition of acquired resistance. In summary, for acquired resistance all patients should have the following criteria: Previous treatment with a targetable drug; either or both of the following: a tumor that harbors an aberration known to be associated with drug sensitivity or objective clinical benefit from treatment with a targetable drug; systemic progression of disease following Response Evaluation Criteria in Solid Tumor or World Health Organization criteria while on continuous treatment and no intervening systemic therapy between cessation of targetable drug and initiation of new therapy [46].

Many mechanisms of acquired resistance have been recognized (Table 2, Fig. 1) [47–57]. They may be divided into: (1) driver oncogene alterations, (2) abnormal signaling pathway alterations in parallel or downstream fashion, (3) pro-survival signaling through a different or unknown signaling pathway, (4) histological transformation from one cell lineage to another, and (5) drug tolerant cancer persister cells [58,59].

(1) Driver oncogene alterations

In certain situations, there are alterations in the target gene, such as mutations and amplifications that allow cells to proliferate even in the presence of an inhibitor. Targeted therapies can impose selective pressures causing aberrancies that activate the reengagement of the driver oncogene. Malignant tumors bearing specific aberrancies have significant initial responses to selective inhibitors. Unfortunately, resistance tends to develop over time. Examples of genetic aberrations in the target gene as a mechanism of resistance include secondary mutations after therapy with osimertinib such as EGFR C797S [60]. As well, on initial therapy with erlotinib or gefitinib, EGFR T790M mutations have been found to confer resistance [47].

On-target resistance has been reported in patients with mutations in ALK (L1196M) and ROS-1 (L2026M) treated with crizotinib [56]. The same can be said for other targeted therapies available for NSCLC, as outlined in Table 2.

(2) Off-target resistance

Off-target resistance relates to abnormal activation of: (1) downstream or parallel bypass signaling, (2) presence of co-dominant driver oncogenes, (3) lineage plasticity, (4) epithelial-mesenchymal transition (EMT), and (5) persister cancer cells [61] (Figs. 1 and 2).

1) Downstream or parallel bypass signaling

There are three major oncogenic signaling pathways that drive cell growth, proliferation and metabolism of cells: the PI3K/AKT/mTOR (PI3K pathway), RAS/RAF/ERK (MAPK pathway), and STAT/JAK pathways [7] (Fig. 2).

Some of the most common abnormal signal activation processes follow gain-of-function mutations, genomic amplification, chromosomal rearrangements, or autocrine activation. A gain-of-function mutation develops when downstream signaling is abrogated despite upstream blockade by targeted agents. Gene amplification is an increase in the number of copies of a gene sequence. It occurs in cancer cells when multiple copies of genes are produced in response to signals from other cells or their environment [62]. Chromosomal rearrangements can lead to cancer either by forming a hybrid gene or by causing dysregulation of a gene [63]. Autocrine signaling is defined as the production and secretion of an extracellular mediator by a cell followed by the binding of that mediator to receptors on the same cell to initiate signaling [64].

In BRAF mutant malignancies, treatment with BRAF inhibitors lead to amplification or activating of mutations that restore downstream MAPK signaling [65]. In NSCLC, adding a downstream MEK inhibitor to BRAF inhibitors improved duration of responses from 6.3 months to 10.2 months [26,66].

MET amplification increases sensitivity of hepatocyte growth factor signals and increases flux through the PI3K/AKT-mTOR axis, thus bypassing EGFR TKI inhibition [65]. This is the most common “bypass” resistance mechanism to osimertinib [60]. On the other hand, amplification of ERBB2 is more common resistance mechanism to the first-generation and second-generation EGFR TKIs [67]. Subsequent studies identified other mediators of parallel survival pathway activation in EGFR-mutant lung cancer, including FGFR3 amplification, PIKC3A mutations, and AXL overexpression all of which reactivate downstream MAPK and PI3K signaling [65,68–70].

A resistant mechanism worth mentioning is AXL overexpression. AXL is a receptor tyrosine kinase implicated in cellular proliferation and differentiation, cytoskeletal rearrangement, migration, and survival signaling [71]. AXL is known to mediate biological variables that function as modifiers of therapy resistance such as EMT, the tumor microenvironment and tumor heterogeneity. Intratumor AXL is involved in both intrinsic and adaptive resistance mechanisms in NSCLC. A retrospective study by Taniguchi et al. [72] demonstrated that higher AXL expression negatively correlated with EGFR TKI response, including osimertinib. AXL receptor upregulation results in acquired resistance even in the absence of the EGFR T790M mutation. Inhibition of AXL activation has shown effectiveness in overcoming acquired resistance to EGFR TKI treatment in NSCLC [72]. Dubermatinib (TP-0903) is a small molecule AXL inhibitor. A phase I study of 36 patients demonstrated manageable safety and early signs of biologic activity [73]. Antibody drug conjugates targeting AXL are also in clinical trials. The relation between AXL and other oncogenes (e.g., MET, BRAF, EGFR, ALK) is complex and heterogeneous. Understanding interactions between AXL and other oncogenes could help shape the development of new drugs.

2) Co-dominant driver oncogenes

While apparently single oncogenic drivers have been identified and targeted in NSCLC, it has become clear that a spectrum of non-sensitizing mutations co-exists and these lead to disease resistance to targeted therapies. Various studies have demonstrated inferior outcomes (decreased responsiveness, shorter progression-free survival [PFS] and overall survival [OS]) in patients with TP53 co-mutations in EGFR-mutant NSCLC with TKI therapy [74–76]. This is also seen with other mutation subtypes, including ALK and ROS-1 alterations [77–79]. Recently, Yu et al. [74] molecularly profiled EGFR-mutant tumors before and after disease progression on TKI therapy and demonstrated that in addition to TP53 mutations, concurrent HER2 amplification and MET amplifications were associated with shorter time to disease progression. Additionally, Alidousty et al. [80] demonstrated that the co-occurrence of TP53 mutations in ALK rearranged NSCLC can potentially lead to chromosomal instability leading to amplifications of other known cancer genes in one-fourth of TP53 mutated cases. For instance, 14% of TP53 mutant cases had MYC amplifications. MYC-overexpressing tumor cells have a high proliferative advantage compared to wild-type and this could potentially lead to drug resistance and disease progression.

3) Tumor lineage plasticity

Lineage plasticity is the ability of a cell to transform to a new phenotype that more closely resembles a distinct developmental lineage [81]. Cancer cell plasticity occurs after exposure and selective pressure to targeted therapy agents [81,82]. This transformation allows the tumor cells to adapt to adverse conditions, including a hypoxic tumor microenvironment [81]. Although these transformed cells retain the driver mutation, they are no longer dependent on the driver mutation for proliferation causing therapeutic resistance.

In NSCLC, histologic transformation from adenocarcinoma to small-cell or squamous cell lineage has been identified [83]. These changes have been described in lung adenocarcinoma with EGFR mutations, EML4-ALK fusions and KRAS G12C mutations treated with targeted therapies [84–88].

This switching phenomenon may occur in up to 15% of cases of EGFR-mutated lung adenocarcinoma with acquired resistance [60]. The presence of RB1 and TP53 mutations at baseline are a predictor of small cell lung cancer (SCLC) transformation [81,89]. DNA sequencing of neuroendocrine transformed cells indicates that tumor cells retain the EGFR mutation, suggesting a clonal evolution from adenocarcinoma to SCLC [90,91]. To date, there are no predominant genomic correlations associated with EGFR-mutated adenocarcinoma to squamous histology transformation. Addressing the epigenetic, genomic and microenvironmental factors that drive lineage plasticity will be pivotal for the development of new treatment strategies.

4) Epithelial-mesenchymal transition

EMT is a biological process in which epithelial cells lose their characteristics and acquire mesenchymal features [61]. This process has been implicated in lung tumor progression and metastasis [92]. It is believed to occur by stimulation and activation of intracellular signaling pathways that lead to the downregulation of E-cadherin.

Evidence suggests that EGFR TKIs can cause cells to convert to a mesenchymal phenotype by the decreased expression of E-cadherin, the expression of N-cadherin and other mesenchymal markers [93]. NSCLC cells with acquired resistance to gefitinib or osimertinib have shown EMT characteristics, with a decrease in E-cadherin, and increases in vimentin and stemness, without any secondary EGFR mutations [93,94]. Interestingly, AXL is implicated in the pathogenesis of EMT and preclinical data indicate that AXL inhibitors can restore sensitivity of mesenchymal EGFR-mutant cells to erlotinib [95].

5) Persister cancer cells

The concept of drug tolerant persister cells (DTP) has gained recent attention. Persister cancer cells are defined as a population of cells that survive systemic treatments by entering a reversible and slow proliferation state [96,97]. These cells are thought to be different from cancer stem cells (CSCs). Persister cells tend to lack classic drug resistance driver alterations and their resistant phenotype could be transient and reversible upon removal of the treatment drug [98]. In contrast, CSCs are cells within a tumor with the ability to self-renew and generate heterogenous lineages of cancer cells [99]. Despite standard of care treatments, persister cells survive and eventually develop resistance pathways. This leads to abnormal survival and cell growth in relapse sites.

The survival of persister cells is thought to occur due to pre-existent drug-resistant cells or by induction of intrinsic changes that promote phenotypic variations. As malignant cells proliferate, they are subjected to different pressures, metabolic, hypoxic and nutritional limitations [59]. A series of case reports show how EGFR inhibitors induce chromatin repression, adding to mechanisms that influence the development and survival of DTPs [97].

New studies are focused on identifying, understanding, and targeting DTPs. There is increasing interest in eliminating, reducing, or suppressing DTPs as a critical step for improving response and clinical outcomes [59,98]. Other strategies in oligometastatic disease may follow local control by surgical resection or radiation therapy, as they have shown to prolong PFS in small studies [100].

Sequential tissue biopsies combined with genetic sequencing may allow for better characterization of evolving tumor characteristics. There is a clear need of understanding the role of DTP in NSCLC and its role in the design of treatment strategies

Toxicity

Targeted therapies are designed to disrupt genetic aberrancies that act as drivers in cancer development. Although quite tolerable after short term exposures, because they tend to be used for chronic continuous administration, they come at the expense of significant toxicities. Targeted agents were initially presumed to be relatively non-toxic since they abrogate cancer specific targets. However, their “on target” and “off target” effects can lead to toxicity. Either of these adverse reactions may prevent the recommended schedule and dose of therapy, thus potentially limiting drug efficacy. Common adverse events of target therapies are summarized in Table 1 [6,13–35].

1. On-target toxicity

On-target toxicity occurs when a protein is inhibited in normal cells. Targeted agents were initially presumed to be relatively non-toxic since they were designed to abrogate cancer specific targets. However, because of complexities of cell signaling and our agents not being able to strictly and selectively block aberrant proteins in the cancer cells, inhibiting a fixed set of proteins in the normal cells causes toxicity by inhibiting the signaling pathway. These on-target toxicities exhibit a class effect where all the drugs in the same class have similar toxicity. For instance, hyperglycemia with PI3K-inhibition, hypertension with vascular endothelial growth factor inhibition and skin rash with EGFR inhibition [101–103].

As mentioned above, EGFR inhibitors, as a class, are associated with cutaneous side effects such as rash, dry skin and pruritus. These events are thought to occur due to the high expression of EGFR in the epidermis and the release of inflammatory cytokines by EGFR inhibitors [103,104]. These symptoms generally appear within the first week of treatment and peaks in intensity around the second week of therapy. Third generation inhibitors are more selective for mutant EGFR. Thus, skin rash associated with EGFR inhibition by osimertinib is much milder as compared with first-generation EGFR TKIs.

(1) Off-target toxicity

Off-target toxicity occurs when a particular drug blocks a non-target protein leading to a deleterious side effect. This, as a rule, does not exhibit a class effect and is thought to be related to the pharmacology of the specific drug. One of the classical examples is the cardiac toxicity which is associated with osimertinib but not with gefitinib. Cardiovascular toxicity associated with osimertinib include heart failure, left ventricular dysfunction, conduction abnormalities, and myocardial injury or dysfunction [105,106]. EGFR is a receptor tyrosine kinase in the ErbB/HER family which also includes HER2. Osimertinib has modest activity against HER2, possibly explaining its cardiotoxicity [107].

Factors Influencing Toxicity

The broad types of toxicity from targeted agents have been described above. Apart from the inherent drug characteristics leading to “on-target” and “off-target” toxic effects, a number of factors contributing to toxicity have been recognized. These are described below.

1. Age

On average, NSCLC is diagnosed in patients older than 65 years [108]. Treating this sub-group of patients with multiple co-morbidities, who tend to be on multiple drugs is a challenge. More importantly, they tend to be underrepresented in pivotal trials.

In a phase III study, a geriatric population with advanced EGFR-mutant NSCLC and treated with erlotinib versus placebo was evaluated for treatment toxicities. Elderly (> 70 years of age) patients treated with erlotinib experienced greater toxicity: 35% versus 18% (grade > 3; p < 0.001) [109]. The increased toxicities reported in the elderly included rash, stomatitis, dehydration, anorexia, and fatigue. Response rates were similar between age groups, but at the cost of increased toxicity.

A retrospective multicenter study evaluated patients > 80 years old with EGFR mutations to assess efficacy and tolerance of TKIs [110]. The overall response rate and disease control rates were 63.3% and 78.9%, respectively. Median PFS and median OS were 11.9 months and 20.9 months, respectively. The predominant toxicities were cutaneous for 66.7% of patients (grade 3–4, 10%), diarrhea for 56.0% (grade 3–4, 15%; grade 5, 2%) and others for 25.7% (grade 3–4, 41%). Octogenarians with EGFR-mutated NSCLC treated by EGFR TKI had clinical outcomes and toxicity profile comparable to younger patients.

In summary, it would appear that older patients with oncogene driven tumors derive the same benefit as younger patients but with increased toxicity. There have been few studies in this population, but toxicities may be related to diminished organ function. With the aging of the population, it is imperative that studies aimed at understanding mechanisms of toxicity in older adults are performed so that rational approaches to dose adjustments can be defined.

2. Central nervous system toxicity of brain penetrant targeted therapies

In the development of targeted agents for NSCLC, subsequent generations of drugs in each class tend to be more selective with increased central nervous system (CNS) penetration. One of the major concerns with the CNS penetrant drugs has been concomitant CNS toxicity. For instance, lorlatinib, entrectinib and larotrectinib are TKIs with good CNS activity but do have significant CNS toxicity [22,28,111–113]. This creates a challenge in the management of these patients and frequently requires dose interruption and dose reduction. This is further complicated by the fact that a significant number of NSCLC patients with driver mutations will develop CNS metastases [114–116]. Further research is needed to develop CNS penetrant drugs with decreased CNS toxicity.

3. Intermittent scheduling

There are a few cancer types where metastatic disease is curable with systemic therapy. In almost all these cases such as lymphoma, testicular cancer, germ cell tumors, leukemia, Wilms tumors and retinoblastomas, combination therapy is used. The objective of systemic cancer therapy is to reduce the tumor cell population to zero.

Curative systemic therapy generally comprises a combination of agents delivered cyclically at the highest tolerable dose. The Goldie-Coldman hypothesis suggests that tumors undergo a spontaneous mutation of about one cell in 10⁵ cells per gene [117]. At the time of detection, with current imaging, most tumors are about 1 gram, containing 10⁹ cells and, consequently, about 10⁴ resistant clones to a given drug. Resistance to two drugs, however, should be seen in one cell out of 10¹⁰ cells. It, therefore, follows that multidrug therapy will be more effective than single-agent therapy. In addition to overcoming tumor resistance, combination therapy is important in limiting drug toxicity, since several agents with non-overlapping toxicities can be utilized [118].

In spite of the above well-known principles, attempts to combine targeted therapies inhibiting complimentary pathways to prevent resistance and potentially achieve cures have been unsuccessful, because of toxicity. Examples include combinations of EGFR TKIs and mTOR inhibitors, EGFR TKIs and insulin-like growth factor 1 receptor inhibitors, MEK inhibitors and PI3K inhibitors among others [119].

In almost all of these studies, the agents have been dosed continuously. An approach to minimizing toxicity could be evaluation of intermittent dosing as well as sequential schedules, based on robust preclinical data.

4. Drug-drug interactions

Drug interactions that can lead to reduced or increased plasma levels of targeted agents can lead to reduced efficacy or increased toxicity.

Smoking has been reported to alter the metabolism of some targeted agents. In a reported study, current smokers had significantly less erlotinib exposure following a single 150 or 300 mg dose than nonsmokers. Results showed increased metabolic clearance of erlotinib in current smokers [120].

Studies have demonstrated pH-dependent solubility with gefitinib and erlotinib and hence co-administration with H2-blockers or proton pump inhibitors is known to reduce drug exposure and efficacy [121,122].

Additionally, with TKIs which are predominantly metabolized by CYP3A (erlotinib, gefitinib, afatinib, dacomitinib, crizotinib, ceritinib, lorlatinib and dabrafenib), concomitant use of strong CYP3A inhibitors or inducers may increase or decrease the efficacy/toxicity of the TKI respectively [122–124]. Of note, grapefruit is a strong CYP3A inhibitor and St. John’s wort is a strong CYP3A inducer.

5. Food effect

Most available targeted agents are administered orally. Oral bioavailability is determined by absorption and first-pass metabolism [125]. Food can affect drug bioavailability when fat content from food increases bile salt secretion. This in turn increases solubilization and absorption of lipophilic drugs. Also, food substances can bind to the oral drug and limit its absorption [125]. Other factors that can either increase or decrease absorption include a rise in gastrointestinal pH, delay in gastric-emptying rate and increase of splanchnic blood [125–127].

In many clinical trials, drug administration is provided on an empty stomach. This is usually recommended to reduce variability of drug absorption between patients. An example of food effect is seen with osimertinib. The C_max and area under the curve are increased by 14% and 19%, respectively, following a high-fat, high calorie meal when compared to fasting [128]. Food also increases the steady state levels of erlotinib [129]. How different foods and acid reducing agents affects the absorption and efficacy of each targeted therapy needs to be further explored.

Pharmacogenomics

Pharmacogenomics is an evolving branch of pharmacology and seeks to understand the association between genetics, response rates and toxicities [130]. It is an individual variation in drug toxicity and efficacy related to inherited variations in drug transport, metabolism and target enzymes. In a number of cases, specific genetic polymorphisms may be more prevalent in specific ethnic populations. For example, ethnic differences in the distribution of EGFR polymorphisms have been described [131]. Additionally, ethnicity may play a role in drug tolerability. For instance, rate of interstitial lung disease with gefitinib or erlotinib is significantly higher in Japanese population [132]. This example exposes the need of expanding ethnic diversity in clinical trials and understanding the role of germ-line polymorphisms in drug metabolism enzymes in drug toxicity [133,134].

A major challenge to incorporating pharmacogenetics into routine NSCLC care include establishing validation and standardization of genotyping procedures to consistently include the genotyping of normal tissue from each patient and not focus only on tumor tissue [130]. This could help identify germ-line polymorphisms of clinical relevance in each patient.

Integrating pharmacogenetics in NSCLC is an important step in achieving the best personalized medical care, leading to optimizing drug efficacy and minimizing toxicity.

Cost and Access

Cancer drugs are very expensive in the United States (see Table 1 for drug prices). Even though there are multiple drugs in each class targeting an oncogene product, in-class competition does not appear to put a downward pressure on prices as happens in other areas of the economy, and prices continue to remain high [135,136]. Since global pricing follows the United States pricing, targeted drugs for oncogene-addicted NSCLC remain high globally and, in most countries, these agents are unaffordable to the majority of the NSCLC population [136,137].

Conclusion

A new generation of drugs is replacing the chemotherapy-based standard of care in systemic therapy of NSCLC. As with all important innovations, targeted therapies pose unique challenges. An approach to overcoming both primary and acquired resistance in oncology is combination therapy, where drugs inhibiting different pathways are combined to achieve maximum response and prevent the emergence of resistance. This approach has led to the cure of some advanced cancers such as lymphoma and testicular cancers. Because of the chronic oral administration, toxicity of targeted therapy continues to be a major issue which precludes the use of these agents in combination and thus limits the opportunity for cure. Future studies should focus on understanding the mechanisms of toxicity, developing novel drug administration schedules to allow for combination of TKIs targeting complimentary pathways. Studies should also focus on special populations and host factors contributing to variations in toxicity. The lack of affordability of targeted agents by most lung cancer patients in the world is a concern. Global efforts to reduce drug prices is an urgent need.

Notes

Author Contributions

Conceived and designed the analysis: Rivera-Concepcion J, Uprety D, Adjei AA.

Collected the data: Rivera-Concepcion J, Uprety D, Adjei AA.

Contributed data or analysis tools: Rivera-Concepcion J, Uprety D, Adjei AA.

Performed the analysis: Rivera-Concepcion J, Uprety D, Adjei AA.

Wrote the paper: Rivera-Concepcion J, Uprety D, Adjei AA.

Conflicts of Interest

Dr. Adjei and Dr. Rivera-Concepcion declare no conflict of interest.

Dr. Uprety has served as an Advisory Board Member for Daiichi Sankyo Inc. (DSI)and AstraZeneca and has received payment or honoraria from Daiichi Sankyo Inc. (DSI) and AstraZeneca.

Fig. 1

Simplified diagram depicting various possible mechanisms of disease progression at a cellular-level following treatment with a tyrosine kinase inhibitor in oncogenic-addicted non–small cell lung cancer. Genetic mechanisms are further described in Fig. 2.

Fig. 2

Figure depicting signaling pathway in oncogenic-addicted non–small cell lung cancer (NSCLC) (A), mechanism of tyrosine kinase inhibitor (TKI) and various signaling pathways of disease resistance (B), including a gate-keeper mutation (C), bypass signaling (D) and a concurrent-driver oncogene (E). EGFR, epidermal growth factor receptor; MAPK, mitogen-activated protein kinase; NSCLC, non–small cell lung cancer; PI3K, phosphoinositide 3-kinase; TKI, tyrosine kinase inhibitor.

Table 1

List of drugs that has been approved by the U.S. Food and Drug Administration in non–small cell lung cancer with oncogenic driver mutation

Aberrant genes	Drugs	Dosing	Pricing in $US per pill^a)	Common adverse events	Unique/concerning adverse event profile for specific drug
EGFR [6,13–17]	Erlotinib Gefitinib Afatinib Dacomitinib Osimertinib	150 mg QD 250 mg QD 40 mg QD 45 mg QD 80 mg QD	~$300 $311.56 $419.43 $576.92 $608.34	Dry skin to acneiform skin rash Nail changes: tenderness, fissuring and paronychia Diarrhea QT prolongation	Osimertinib: pneumonitis and cardiac failure (rare but can be severe)
ALK [18–22]	Crizotinib Ceritinib Alectinib Brigatinib Lorlatinib	250 mg BID 450 mg QD 600 mg BID 90 mg QD×7 days → 180 mg QD 100 mg QD	$392.18^b) $158.28^c) $82.46^c) $715.03 $714.80 $747.00	Nausea, vomiting Liver enzyme abnormalities Diarrhea Bilirubin rise Peripheral edema CNS effects	Crizotinib: visual disturbance, sinus bradycardia Alectinib: myalgia and creatine phosphokinase elevation Brigatinib: pneumonitis Lorlatinib: hypercholesterolemia, hypertriglyceridemia, edema, CNS effects, peripheral neuropathy
ROS1 [23–25]	Crizotinib Ceritinib Entrectinib	As above As above 600 mg QD	As above As above $237.64^d)	Visual disturbances Nausea, vomiting Diarrhea/constipation Edema Elevation of aminotransferase levels	Crizotinib: visual disturbance Ceritinib: nausea, vomiting, diarrhea, elevation of aminotransferase levels Entrectinib: dysgeusia, nausea, vomiting, diarrhea/constipation, peripheral edema
BRAF V600E [26]	Dabrafenib +Trametinib Dabrafenib Vemurafenib	150 mg BID+ 2 mg QD As above 960 mg QD	$122.44^e) $531.75 As above $54.25^f)	Pyrexia Skin rash Diarrhea Hyperglycemia Nausea, vomiting Peripheral edema Myalgia Squamous cell carcinoma (especially if MEK-inhibitor is not used)	Dabrafenib/vemurafenib monotherapy: skin papillomas, keratoacanthomas and squamous cell carcinoma Trametinib: ocular toxicity, peripheral edema Dabrafenib+trametinib: increased cardiomyopathy, GI toxicity, pyrexia, ocular toxicity but decreased rates of skin papillomas and squamous cell carcinoma
NTRK1/2/3 [27,28]	Larotrectinib Entrectinib	100 mg BID As above	$656.00^g) As above	Elevation of aminotransferase levels Nausea, vomiting Diarrhea, constipation Anemia Weight gain	Entrectinib: dysgeusia, blood creatinine elevation
RET [29,30]	Selpercatinib Pralsetinib	160 mg BID 400 mg QD	$206.00^h) $198.21^g)	Diarrhea/constipation Dry mouth Hypertension Elevation of aminotransferase levels Peripheral edema Hyponatremia Nausea, vomiting Elevated blood creatinine levels Anemia Lymphopenia	-
MET exon 14 skipping [31,32]	Capmatinib Tepotinib	400 mg BID 450 mg QD	$214.06^c)^d) $438.86ⁱ⁾	Peripheral edema Nausea, vomiting Elevated blood creatinine levels Hypoalbuminemia Constipation, diarrhea Dyspnea Fatigue Elevation of alanine transaminase	Capmatinib/tepotinib: peripheral edema, hypoalbuminemia, elevated blood creatinine levels
KRAS G12C [33]	Sotorasib	960 mg QD	$89.50^j)	Nausea, vomiting Diarrhea Elevation of aminotransferase levels Fatigue Arthralgia	-
Exon 20 insertion [34,35]	Amivantamab Mobocertinib	1,050 mg IV 160 mg QD	$539.61^k) $250.00^l)	Infusion-related reaction Diarrhea Nausea, vomiting Skin rash Stomatitis	Amivantamab: infusion-related reaction, ocular toxicity (keratitis, uveitis), peripheral edema and hypoalbuminemia Mobocertinib: significant GI toxicity and skin rash

ALK, anaplastic lymphoma kinase; BID, twice a day oral; EGFR, epidermal growth factor receptor; GI, gastrointestinal; IV, intravenous (split dosing on day 1 and day 2 on week 1 followed by weekly dose for week 2–4 and then every 2 weeks for patients with < 80 kg weight; dosing is different for patients with ≥ 80 kg weight); KRAS G12C, Kirsten rat sarcoma 2 viral oncogene with glycine-to-cysteine substitution at codon 12; MET, mesenchymal epithelial transition; NTRK, neurotrophic tyrosine receptor kinase; QD, once a day oral; RET, rearranged during transfection; ROS1; c-ros oncogene 1; ~, around.

^a) Pricing is per each pill in US $ in the United States (Source: Lexicomp. Facts and comparisons, Accessed February 8, 2022),

^b) Per 250 mg pill,

^c) Per 150 mg pill,

^d) Per 200 mg pill,

^e) Per 75 mg pill,

^f) Per 240 mg pill,

^g) Per 100 mg pill,

^h) Per 80 mg pill,

ⁱ⁾ Per 225 mg pill,

^j) Per 120 mg pill,

^k) 350 mg/7 mL (per mL),

^l) Per 40 mg pill.

Table 2

Common on-target driver-mutation dependent resistant mutation in NSCLC on TKI therapy and potential treatment options

Mutation	Drug	On-target resistant mutation/ driver-mutation dependent resistance	(Potential) Drugs for resistance
EGFR exon 19 deletion, exon 21 L858R	Erlotinib Gefitinib	T790M	Osimertinib [47]
EGFR exon 19 deletion, exon 21 L858R	Osimertinib (1st line)	C797S	1st generation TKI (erlotinib or gefitinib) [48]
EGFR exon 19 deletion, exon 21 L858R	Erlotinib/gefitinib → Osimertinib	C797S/T790M Trans C797S/T790M Cis	Osimertinib+1st generation TKI [48,49] EGFR TKI either alone or in combination not effective [48] Cetuximab+allosteric inhibition (EAI045, preclinical) [50,51]
		C797S/T790M	BLU-945 (4th generation EGFR TKI) [52]
ALK	Crizotinib, ceritinib, alectinib, brigatinib	G1202 R	Lorlatinib [53] Brigatinib (controversial) [54,55]
	Crizotinib	L1196M	Brigatinib, lorlatinib, ensartinib [56]
		G1269A	Ceritinib, alectinib, brigatinib, lorlatinib [56]
ROS1	Crizotinib	G2032R	Rapotrectinib [57]

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC, non–small cell lung cancer; ROS1; c-ros oncogene; TKI, tyrosine kinase inhibitor.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.

3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.

4. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with peme-trexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:2895–902.

5. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:4349–57.

6. Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, et al. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia Pac J Clin Oncol. 2012;8:232–43.

7. Sudhesh Dev S, Zainal Abidin SA, Farghadani R, Othman I, Naidu R. Receptor tyrosine kinases and their signaling pathways as therapeutic targets of curcumin in cancer. Front Pharmacol. 2021;12:772510.

8. Lugowska I, Kosela-Paterczyk H, Kozak K, Rutkowski P. Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther. 2015;8:2251–9.

9. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371–81.

10. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327–44.

11. Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386:241–51.

12. Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, et al. Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers. Clin Cancer Res. 2019;25:64–72.

13. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.

14. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26:2442–9.

15. Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:1454–66.

16. Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577–89.

17. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50.

18. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–38.

19. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.

20. Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389:917–29.

21. Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Hochmair MJ, et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J Clin Oncol. 2020;38:3592–603.

22. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383:2018–29.

23. Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30:1121–6.

24. Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35:2613–8.

25. Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol. 2021;39:1253–63.

26. Planchard D, Besse B, Groen HJ, Hashemi SM, Mazieres J, Kim TM, et al. Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis. J Thorac Oncol. 2022;17:103–15.

27. Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21:531–40.

28. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21:271–82.

29. Drilon A, Oxnard GR, Tan DS, Loong HH, Johnson M, Gainor J, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020;383:813–24.

30. Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021;22:959–69.

31. Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJ, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383:944–57.

32. Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383:931–43.

33. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207–17.

34. Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39:3391–402.

35. Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;7:e214761.

36. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711–23.

37. Mielgo-Rubio X, Martin M, Remon J, Higuera O, Calvo V, Jarabo JR, et al. Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges. Future Oncol. 2021;17:4011–25.

38. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25.

39. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81–94.

40. Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria JC. Overcoming resistance to tumor-targeted and immune-targeted therapies. Cancer Discov. 2021;11:874–99.

41. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376:2109–21.

42. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.

43. Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila). 2010;3:1361–4.

44. Lovly CM, Salama AK, Salgia R. Tumor heterogeneity and therapeutic resistance. Am Soc Clin Oncol Educ Book. 2016;35:e585–93.

45. Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 2015;5:713–22.

46. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Janne PA, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28:357–60.

47. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629–40.

48. Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res. 2015;21:3924–33.

49. Arulananda S, Do H, Musafer A, Mitchell P, Dobrovic A, John T. Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer. J Thorac Oncol. 2017;12:1728–32.

50. Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534:129–32.

51. Wang S, Song Y, Liu D. EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett. 2017;385:51–4.

52. Schalm SS, Dineen T, Lim SM, Park CW, Hsieh J, Woessner R, et al. 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC. Ann Oncol. 2020;31(Suppl 4):S839.

53. Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, et al. ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J Clin Oncol. 2019;37:1370–9.

54. Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, et al. The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin Cancer Res. 2016;22:5527–38.

55. Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35:2490–8.

56. Pan Y, Deng C, Qiu Z, Cao C, Wu F. The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer. Front Oncol. 2021;11:713530.

57. Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, et al. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations. Cancer Discov. 2018;8:1227–36.

58. Neel DS, Bivona TG. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. NPJ Precis Oncol. 2017;1:3.

59. Mikubo M, Inoue Y, Liu G, Tsao MS. Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. J Thorac Oncol. 2021;16:1798–809.

60. Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725–37.

61. Marine JC, Dawson SJ, Dawson MA. Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020;20:743–56.

62. Albertson DG. Gene amplification in cancer. Trends Genet. 2006;22:447–55.

63. Holland AJ, Cleveland DW. Chromoanagenesis and cancer: mechanisms and consequences of localized, complex chromosomal rearrangements. Nat Med. 2012;18:1630–8.

64. Ungefroren H. Autocrine TGF-beta in cancer: review of the literature and caveats in experimental analysis. Int J Mol Sci. 2021;22:977.

65. Tulpule A, Bivona TG. Acquired resistance in lung cancer. Annu Rev Cancer Biol. 2020;4:279–97.

66. Mazieres J, Cropet C, Montane L, Barlesi F, Souquet PJ, Quantin X, et al. Vemurafenib in non-small-cell lung cancer patients with BRAF(V600) and BRAF(nonV600) mutations. Ann Oncol. 2020;31:289–94.

67. Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018;17:53.

68. Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4:61.

69. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–7.

70. Zhang GC, Lin JY, Wang Z, Zhou Q, Xu CR, Zhu JQ, et al. Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients. Clin Oncol (R Coll Radiol). 2007;19:499–506.

71. Zhang G, Wang M, Zhao H, Cui W. Function of Axl receptor tyrosine kinase in non-small cell lung cancer. Oncol Lett. 2018;15:2726–34.

72. Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat Commun. 2019;10:259.

73. Sarantopoulos J, Fotopoulos G, Tsai FY, Beg MS, Adjei AA, Lou Y, et al. A phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours. Ann Oncol. 2019;30(Suppl 5):V172.

74. Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, Kim R, et al. Concurrent alterations in EGFR-Mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance. Clin Cancer Res. 2018;24:3108–18.

75. Roeper J, Falk M, Chalaris-Rissmann A, Lueers AC, Ramdani H, Wedeken K, et al. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC. Oncotarget. 2020;11:250–64.

76. Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res. 2017;23:2195–202.

77. Wang WX, Xu CW, Chen YP, Liu W, Zhong LH, Chen FF, et al. TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib. J Thorac Dis. 2018;10:2991–8.

78. Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29:2068–75.

79. Gen L, Xu H, Zhao J, Kong J, Ai X, Yu F, et al. Concurrent TP53 mutation adversely impact the efficacy of crizotinib in ROS1-rearranged lung cancer patients. J Clin Oncol. 2019;37(15_Suppl):e20535.

80. Alidousty C, Baar T, Martelotto LG, Heydt C, Wagener S, Fassunke J, et al. Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations. J Pathol. 2018;246:67–76.

81. Quintanal-Villalonga A, Chan JM, Yu HA, Pe’er D, Sawyers CL, Sen T, et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020;17:360–71.

82. Zellmer VR, Zhang S. Evolving concepts of tumor heterogeneity. Cell Biosci. 2014;4:69.

83. Lee JK, Lee J, Kim S, Kim S, Youk J, Park S, et al. Clonal history and genetic predictors of transformation Into small-cell carcinomas from lung adenocarcinomas. J Clin Oncol. 2017;35:3065–74.

84. Takegawa N, Hayashi H, Iizuka N, Takahama T, Ueda H, Tanaka K, et al. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib. Ann Oncol. 2016;27:953–5.

85. Fujita S, Masago K, Katakami N, Yatabe Y. Transformation to SCLC after treatment with the ALK inhibitor alectinib. J Thorac Oncol. 2016;11:e67–72.

86. Hobeika C, Rached G, Eid R, Haddad F, Chucri S, Kourie HR, et al. ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment? Per Med. 2018;15:111–5.

87. Zhang Y, Qin Y, Xu H, Yao Q, Gao Y, Feng Y, et al. Case report: a case report of a histological transformation of ALK-rearranged adenocarcinoma with high expression of PD-L1 to squamous cell carcinoma after treatment with alectinib. Pathol Oncol Res. 2021;27:637745.

88. Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med. 2021;384:2382–93.

89. Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6:6377.

90. Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, et al. Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discov. 2021;11:3028–3047.

91. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.

92. Sung WJ, Kim H, Park KK. The biological role of epithelial-mesenchymal transition in lung cancer (Review). Oncol Rep. 2016;36:1199–206.

93. Weng CH, Chen LY, Lin YC, Shih JY, Lin YC, Tseng RY, et al. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene. 2019;38:455–68.

94. Zhu X, Chen L, Liu L, Niu X. EMT-mediated acquired EGFR-TKI resistance in NSCLC: mechanisms and strategies. Front Oncol. 2019;9:1044.

95. Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019;18:153.

96. Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, Hutter JC, et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature. 2021;596:576–82.

97. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69–80.

98. Cabanos HF, Hata AN. Emerging insights into targeted therapy-tolerant persister cells in cancer. Cancers (Basel). 2021;13:2666.

99. Zakaria N, Satar NA, Abu Halim NH, Ngalim SH, Yusoff NM, Lin J, et al. Targeting lung cancer stem cells: research and clinical impacts. Front Oncol. 2017;7:80.

100. Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672–82.

101. Khan KH, Wong M, Rihawi K, Bodla S, Morganstein D, Banerji U, et al. Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management. Oncologist. 2016;21:855–60.

102. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol. 2010;30:591–601.

103. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer. 2006;8(Suppl 1):S7–14.

104. Chu CY, Choi J, Eaby-Sandy B, Langer CJ, Lacouture ME. Osimertinib: a novel dermatologic adverse event profile in patients with lung cancer. Oncologist. 2018;23:891–9.

105. Kunimasa K, Kamada R, Oka T, Oboshi M, Kimura M, Inoue T, et al. Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib. JACC CardioOncol. 2020;2:1–10.

106. Van Leeuwen MT, Luu S, Gurney H, Brown MR, Pearson SA, Webber K, et al. Cardiovascular toxicity of targeted therapies for cancer: an overview of systematic reviews. JNCI Cancer Spectr. 2020;4:pkaa076.

107. Uprety D, Mansfield AS. Targeting the cardiotoxicity of epidermal growth factor receptor inhibitors. JACC CardioOncol. 2020;2:11–2.

108. Chen T, Zhou F, Jiang W, Mao R, Zheng H, Qin L, et al. Age at diagnosis is a heterogeneous factor for non-small cell lung cancer patients. J Thorac Dis. 2019;11:2251–66.

109. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:2350–7.

110. Corre R, Gervais R, Guisier F, Tassy L, Vinas F, Lamy R, et al. Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). Oncotarget. 2018;9:8253–62.

111. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731–9.

112. Drilon A, Tan DS, Lassen UN, Leyvraz S, Liu Y, Patel JD, et al. Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers. JCO Precis Oncol. 2022;6:e2100418.

113. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19:1654–67.

114. Kelly WJ, Shah NJ, Subramaniam DS. Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer. Front Oncol. 2018;8:208.

115. Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:JCO2018783118.

116. Griesinger F, Roeper J, Pottgen C, Willborn KC, Eberhardt WE. Brain metastases in ALK-positive NSCLC: time to adjust current treatment algorithms. Oncotarget. 2018;9:35181–94.

117. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727–33.

118. DeVita VT, Lawrence TS, Rosenberg SA. Devita, Hellman and Rosenberg’s cancer: principles and practice of oncology. 9th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.

119. Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, et al. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2012;7:419–26.

120. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006;12:2166–71.

121. Solassol I, Pinguet F, Quantin X. FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management. Biomolecules. 2019;9:668.

122. Peters S, Zimmermann S, Adjei AA. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev. 2014;40:917–26.

123. Zhao D, Chen J, Chu M, Long X, Wang J. Pharmacokinetic-based drug-drug interactions with anaplastic lymphoma kinase inhibitors: a review. Drug Des Devel Ther. 2020;14:1663–81.

124. Suttle AB, Grossmann KF, Ouellet D, Richards-Peterson LE, Aktan G, Gordon MS, et al. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. J Clin Pharmacol. 2015;55:392–400.

125. Willemsen AE, Lubberman FJ, Tol J, Gerritsen WR, van Herpen CM, van Erp NP. Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today. 2016;21:962–76.

126. Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet. 2004;43:1127–56.

127. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11–23.

128. Chu E, DeVita VT Jr. Physicians’ cancer chemotherapy: drug manual 2021. Burlington, MA: Jones & Bartlett Learning; 2022.

129. Ling J, Fettner S, Lum BL, Riek M, Rakhit A. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs. 2008;19:209–16.

130. Ruwali M, Moharir K, Singh S, Aggarwal P, Paul MK. Updates in pharmacogentetics of non-small cell lung cancer [Internet]. London: IntechOpen; 2021. [cited 2021 Dec 10]. Available from: https://doi.org/10.5772/intechopen.97498

131. Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P, et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med. 2007;4:e125.

132. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24:2549–56.

133. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005;10:461–6.

134. Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol. 2017;14:57–66.

135. Desai A, Scheckel C, Jensen CJ, Orme J, Williams C, Shah N, et al. Trends in prices of drugs used to treat metastatic non-small cell lung cancer in the US from 2015 to 2020. JAMA Netw Open. 2022;5:e2144923.

136. Shih YC, Smieliauskas F, Geynisman DM, Kelly RJ, Smith TJ. Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J Clin Oncol. 2015;33:2190–6.

137. Shilpakar R, Paudel BD, Sharma R, Silwal SR, Sapkota R, Shrestha P, et al. Lung cancer in Nepal. J Thorac Oncol. 2022;17:22–9.